1. 7. 2016

Hotel Holiday Inn, Bratislava

• Slovenská lekárska spoločnosť
• Slovenská onkologická spoločnosť

• MUDr. Mária Rečková
• MUDr. Juraj Beniak

Podujatie bude ohodnotené  6 CME kreditmi

Odborný program

8.00 – 8.30 Registration

8.30 – 8.35 Welcome

President of Slovak Oncology Society, Tomáš Šálek

I. Gastrointestinal Cancer Session

Chairmen: Tomáš Šálek, Juraj Detvay (8.35 – 9.40)

8.35 – 8.55 1. Gastrointestinal cancer (Colorectal) (Juraj Detvay, FNsP Nitra)

1. Abstract # 3504 Impact of primary (1o) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). (Alan P. Venook)
2. Abstract # 3507 CREST: Randomised phase III study of stenting as a bridge to surgery in obstructing colorectal cancer – Results of the UK ColoRectal Endoscopic Stenting Trial (CREST). (James Hill)
3. Abstract # 3511 The potential of circulating tumor DNA (ctDNA) to reshape the design of clinical trials testing adjuvant therapy in patients with early stage cancers. (Jeanne Tie)
4. Abstract # 3512 FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized study—Prodige 14 – Accord 21 (METHEP-2), a UNICANCER GI trial. (Marc Ychou)
5. Abstract # 3503 NCI9673: A Multi-Institutional ETCTN Phase 2 Study of Nivolumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal (SCCA). (Van Karlyle Morris II)

8.55 – 9.15 2. Gastrointestinal (Non-Colorectal) Cancer (Tomáš Šálek, NOÚ Bratislava)

1. Abstract # LBA4001 FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a firstin- class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma. (Salah- Eddin Al-Batran)
2. Abstract # 4003 Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)- CALGB 80802 (Alliance). (Ghassan K. Abou-Alfa)
3. Abstract # 4005 NETTER-1 Phase III: Efficacy and Safety Results in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate. (Jonathan R. Strosberg)
4. Abstract # 4000 A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer: First results from the CRITICS study. (Marcel Verheij)
5. Abstract # LBA4006 ESPAC-4: A multicenter, international, open label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP), versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. (John P. Neoptolemos)

9.15 – 9.40 Discussion

II. Head&Neck Cancer / Melanoma&Skin Cancers Session

Chairmen: Juraj Beniak, Pavol Dubinský, Róbert Godál (9.40 – 10.45)

9.40 – 10.00 3. Head&Neck Cancer (Pavol Dubinský, VOÚ Košice)

1. Abstract # LBA2 A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677). (James R. Perry)
2. Abstract # 6007 Gemcitabine plus cisplatin (GP) versus 5-FU plus cisplatin (FP) as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC): A randomized, open-label, multicenter, phase III trial. (Li Zhang)
3. Abstract # 6000 Induction taxotere platinum 5-FU (TPF) followed by cetuximabradiotherapy
   versus concurrent chemo-radiotherapy in patients with N2b-N3 (non operated Stage III-IV) squamous cell cancer of the head and neck (SCCHN): Results of the GORTEC 2007-02 phase III randomized trial. (Lionnel Geoffrois)
4. Abstract #6009 Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141. (Robert L. Ferris)
5. Abstract # 6011 Preliminary results from KEYNOTE-055: pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC). (Joshua Bauml)

10.00 – 10.20 4. Melanoma&Skin Cancers (Róbert Godál, NOÚ Bratislava)

1. Abstract # 9503 Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE- 001. (Caroline Robert)
2. Abstract # 9505 Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment- naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). (Jedd D. Wolchok)
3. Abstract # 9506 Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort. (Georgina V. Long)
4. Abstract # 9504 Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE- 006. (Jacob Schachter)
5. Abstract # 9502 Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. (Keith T. Flaherty)

10.20 – 10.45 Discussion

10.45 – 11.05 Coffee-Break

III. Lung Cancer&Mesothelioma / Patient and Survivor Care Session

Chairmen: Peter Kasan, Peter Beržinec, Andrea Škripeková (11.05 – 12.05)

11.05 – 11.25 5. Patient and Survivor Care (Andrea Škripeková, NOÚ Bratislava)

1. Abstract # 10001 Comorbidities and risk of chemotherapy induced peripheral neuropathy among participants in SWOG clinical trials. (Dawn L. Hershman)
2. Abstract # 10006 Benefits of Physician orders for Scope of Treatment (POST) forms on end-of-life care in cancer patients: Insights from the West Virginia registry. (Mark W. Knestrick)
3. Abstract # 10000 A URCC NCORP nationwide randomized controlled trial investigating the effect of exercise on chemotherapy-induced peripheral neuropathy in 314 cancer patients. (Ian Kleckner)
4. Abstract # 10003 Randomized trial of early integrated palliative and oncology care. (Jennifer S. Temel)
5. Abstract # 10019 Placebo-controlled phase III study comparing dexamethasone on day1 to on day1-3 with NK1 receptor antagonist and palonosetoron in high emetogenic chemotherapy. (Kunihiro Matsuzaki)

11.25 – 11.45 6. Lung Cancer (Peter Beržinec, ŠN Sv. Svorada, Nitra)

1. Abstract # 9004 Local Consolidative Therapy (LCT) Improves Progression-Free Survival (PFS) in Patients with Oligometastatic Non-Small Cell Lung Cancer (NSCLC) who Receive Induction Systemic Therapy (IST): Results of a Multi-Institutional Phase II Randomized Study. (Daniel Richard Gomez)
2. Abstract # 9012 A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): LURET study. (Takashi Seto)
3. Abstract # 108 Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC). (Alexander E. Drilon)
4. Abstract # 9008 Primary analysis for alectinib versus crizotinib in ALK-inhibitor naïve ALK positive non-small cell lung cancer (ALK+ NSCLC) in randomized open-label
   phase III trial (J-ALEX study). (Hiroshi Nokihara)
5. Abstract # 8500 Bayesian randomized trial comparing intensity modulated radiation therapy versus passively scattered proton therapy for locally advanced non-small cell lung cancer. (Zhongxing X. Liao)
6. Abstract # 8507 E1505: Adjuvant chemotherapy +/- bevacizumab for early stage NSCLC—Outcomes based on chemotherapy subsets. (Heather A. Wakelee)
7. Abstract # LBA8505 Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3) – targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC). (Charles M. Rudin)
8. Abstract # 8504 CONVERT: An international randomised controlled trial of concurrent chemo-radiotherapy (cCTRT) comparing twice-daily (BD) and oncedaily (OD) radiotherapy (RT) schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS) (NCT00433563). (Corinne Faivre- Finn)

11.45 – 12.05 Discussion

12.05 – 13.05 Lunch

IV. Genitourinary Cancer / Gynecologic Cancer Session

Chairmen: Vladimír Malec, Michal Mego, Branislav Bystrický (13.05 – 14.10)

13.05 – 13.25 7. Genitourinary Cancer (Michal Mego, NOÚ Bratislava)

1. Abstract # 5006 Cabazitaxel vs docetaxel in chemotherapy-naive (CN) patients with metastatic catration-resistant prostate cancer (mCRPC): A three-arm phase III study (FIRSTANA). (A. Oliver Sartor)
2. Abstract # 5008 Phase III non-inferiority study of cabazitaxel C 20 mg/m2 (C20) versus 25 mg/m2 (C25) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D). (Johann S. De Bono)
3. Abstract # 5001 A randomized phase III trial between adjuvant docetaxel and surveillance after radical prostatectomy for high-risk prostate cancer: Results of SPCG12. (Goran Ahlgren)
4. Abstract # 5003 A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. (Charles N Catton)
5. Abstract # 5004 Quality of life (QOL) analysis from CHAARTED: Chemohormonal androgen ablation randomized trial in prostate cancer (E3805). (Linda J. Patrick-Miller)
6. Abstract # 4506 Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC). (Toni K. Choueiri)
7. Abstract # LBA4500 Atezolizumab (atezo) as first-line (1L) therapy in cisplatinineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1. (Arjun Vasant Balar)
8. Abstract #4503 Limited versus extended pelvic lymphadenectomy in patients with bladder cancer undergoing radical cystectomy: Survival results from a prospective, randomized trial (LEA AUO AB 25/02). (Jeurgen E. Gschwend)

13.25 – 13.45 8. Gynecologic Cancer (Branislav Bystrický, FNsP Trenčín)

1. Abstract # 5501 Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: An interim analysis. (Jonathan A. Ledermann)
2. Abstract # 5507 Performance characteristics and stage distribution of invasive epithelial ovarian/tubal/peritoneal cancers in UKCTOCS. (Usha Menon)
3. Abstract # LBA5503 OV21/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) vs. intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC). (Helen Mackay)
4. Abstract # 5508 Baseline quality of life (QOL) as a predictor of stopping chemotherapy early, and of overall survival, in platinum-resistant/refractory ovarian cancer (PRROC): The GCIG Symptom Benefit Study (SBS). (Felicia Roncolato)

13.45 – 14.10 Discussion

V. Breast Cancer Session

Chairmen: Mária Wagnerová, Jozef Mardiak, Stanislav Špánik (14.10 – 15.15)

14.10 – 14.30 9. Breast Cancer – HER2/ER+ (Stanislav Špánik, OÚSA Bratislava)

1. Abstract # LBA1 A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. (Paul E. Goss)
2. Abstract # 512 Efficacy of palbociclib plus fulvestrant (P+F) in patients (pts) with metastatic breast cancer (MBC) and ESR1 mutations (mus) in circulating tumor DNA (ctDNA). (Nicholas C. Turner)
3. Abstract # 507 PALOMA-2: Primary results from a phase 3 trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/ HER2– advanced breast cancer (ABC). (Richard S. Finn)
4. Abstract # 500 Pathologic complete response rates after neoadjuvant trastuzumab emtansine (T-DM1) + pertuzumab vs docetaxel + carboplatin + trastuzumab + pertuzumab treatment in patients with HER2-positive early breast cancer (KRISTINE). (Sara A. Hurvitz)
5. Abstract # LBA503 Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O vs Herceptin. (Nicholas C. Turner)

14.30 – 14.50 10. Breast Cancer – Triple-Negative / Local Therapy (Jozef Mardiak, NOÚ Bratislava)

1. Abstract # 1000 Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49 [NRG Oncology]) comparing docetaxel + cyclophosphamide (TC) v anthracycline/taxanebased chemotherapy regimens (TaxAC) in women with high-risk, HER2-negative breast cancer. (Joanne Lorraine Blum)
2. Abstract # 1007 Ten-year survival results of ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node (Alliance). (Armando E. Giuliano)
3. Abstract # 1005 A randomized controlled trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer: Turkish Study (Protocol MF07-01). (Atilla Soran)
4. Abstract # LBA509 Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN- 38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results. (Aditya Bardia)

14.50 – 15.15 Discussion

15.15 – 15.20 Closing remarks

President of Slovak Oncology Society, Tomáš Šálek

FAREWELL

Pre účastníkov je ubytovanie zabezpečenév mieste konania: Hotel Holiday Inn, Bratislava www.holidayinn.sk.

Ceny ubytovania:

• dvojlôžková izba – 99 €

(cena je uvedená s DPH, zahŕňa ubytovanie, raňajky, miestny poplatok)*

Ubytovanie je možné rezervovať prostredníctvom organizátora podujatia písomnou formou – prihláška na ubytovanie je súčasťou registračného formulára.

Rezervácia je záväzná, zmena je možná bez účtovania storno poplatku do 29. 5. 2016. Po tomto termíne sa o možnostiach ubytovania informujte u organizátora.

SOLEN, s.r.o.

Ambrova 5

831 01 Bratislava

Tel. 02/5413 1365

www.solen.sk

kongres@solen.sk

obchod@solen.sk